drugset / Trial / NCT06511869
AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26)
NaSingle-groupOpen-labelTreatment
Summary
This study is intended to assess the safety and anti-tumor activity of AZD4205 at 150 mg once daily in participants with PTCL who have achieved tumor response after first-line systemic therapy (with or without combination radiotherapy) and are ineligible for HSCT assessed by the investigator as ineligible for HSCT or have no plan for HSCT.
Timeline
- Start
- 2022-03-17
- Primary completion
- 2025-03-31
- Completion
- 2025-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Golidocitinib | Small molecule | 150 mg | Oral |